# Mike Carusi

> Mike Carusi is a Series B investor at Advanced Technology Ventures backing Medical. See 17 investments, check sizes, portfolio and contact details. Updated…

- Type: Angel Investor
- Fund: [Advanced Technology Ventures](https://shizune.co/investors/profile/advanced-technology-ventures)
- Location: Menlo Park, United States
- Total investments: 17
- Last investment: Jun 2025
- Lead investor: 29%
- Last updated: Oct 2026

Mike Carusi is a Series B investor at Advanced Technology Ventures in Menlo Park focused on Medical and Health Care. Mike is a General Partner of Advanced Technology Ventures (ATV) and focuses on investments in the biopharmaceutical and medical device sectors. He is based in the firm’s Palo Alto, CA office, where he also serves as a General Partner and Team Leader for Lightstone Ventures. His representative investments include Altura Medical, Ardian(acquired by Medtronic), EndoGastric Solutions, GI Dynamics (ASX: GID), GluMetrics, Holaira, MicroVention (acquired by Terumo), NeuroVista, Plexxikon (acquired by Daiichi Sankyo), PowerVision, Second Genome, and TranS1 (NASDAQ: TSON).Featured on the Forbes Midas List of top technology investors, Mike is a recognized thought leader in the industry and a frequent speaker at healthcare conferences. He serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum, sits on the Tuck MBA Advisory Board, and is an advisory board member to the UCSF/Berkeley Venture Innovation Program.

## Contacts

5 contacts available for Mike Carusi: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/mike-carusi?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 6 | 35% |
| Health Care | 6 | 35% |
| Biotechnology | 5 | 29% |
| Medical Device | 5 | 29% |
| Therapeutics | 3 | 18% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 18% |
| Series C | 3 | 18% |
| Series D | 3 | 18% |
| Series A | 2 | 12% |
| Series E | 1 | 6% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 47% |
| France | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Allay Therapeutics | Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | $57.5M | Series D | Jun 05, 2025 | https://www.allaytx.com |
| Trotana Therapeutics | Trotana Therapeutics is a biotech company that focuses on the discovery and development of medicines targeting RNA-binding proteins. | $52.5M | Series A | Feb 01, 2025 | https://trotana.com |
| Nuvaira | Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | $79M | Series E | Feb 11, 2019 | https://www.nuvaira.com/ |
| EndoGastric Solutions | EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $40.6M | Series I | Jun 19, 2018 | http://www.endogastricsolutions.com |
| Second Genome | Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners acrossgovernment, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases. | $51M | Series B | Apr 20, 2016 | http://www.secondgenome.com |
| EndoGastric Solutions | EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $50M | Venture - Series Unknown | Dec 01, 2015 | http://www.endogastricsolutions.com |
| EndoGastric Solutions | EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0procedure—a minimally invasive solution that addresses a significant unmet clinical need.EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington. | $30M | Series G | May 06, 2014 | http://www.endogastricsolutions.com |
| Nuvaira | Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease.It was founded in 2008and headquartered in Minneapolis, Minnesota. | $42M | Series D | Apr 03, 2014 | https://www.nuvaira.com/ |
| PowerVision | PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clearvision at all distances.Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s.PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does.For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again. | $20M | Series D | Jan 29, 2014 | http://powervisionlens.com/ |
| Second Genome | Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners acrossgovernment, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases. | $6.5M | Series A | Jun 05, 2013 | http://www.secondgenome.com |

10 of 17 investments shown.

## Co-investors
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 7 deals together
- [Split Rock Partners](https://shizune.co/investors/profile/split-rock-partners) — VC Fund, 6 deals together
- [Chicago Growth Partners](https://shizune.co/investors/profile/chicago-growth-partners) — VC Fund, 5 deals together
- [Radius Ventures](https://shizune.co/investors/profile/radius-ventures) — VC Fund, 5 deals together
- [Foundation Medical Partners](https://shizune.co/investors/profile/foundation-medical-partners) — VC Fund, 4 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 4 deals together

## About Advanced Technology Ventures

VC Fund · Menlo Park, United States

Advanced Technology Ventures (ATV) is a bi-coastal venture capital firm that focuses on communications, infrastructure, software and services, consumer technology, biopharmaceuticals, medical devices and cleantech.

5 contacts available at Advanced Technology Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Bill Wiberg | General Partner | https://shizune.co/investors/profile/bill-wiberg |
| Bob Hower | General Partner | https://shizune.co/investors/profile/bob-hower |
| Jean George | General Partner | https://shizune.co/investors/profile/jean-george |
| Mike Carusi | General Partner | https://shizune.co/investors/profile/mike-carusi |
| Richard Popp | Venture Partner | — |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Mike Carusi invest in?

Mike Carusi invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Series C stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Mike Carusi?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Mike Carusi last invest?

The most recent investment recorded for Mike Carusi closed in Jun 2025. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co